🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Never let the sun set on a rejected manuscript. Resubmit right away. Your hard work cannot lay there sitting unpublished. Probably a little obsessive- but thats my policy haha 🤷‍♂️

Super excited for my wife to be starting her MPH from UMass Amherst!! 📚📚📚

Blind adherence to guidelines and diagnostic criteria: For pts without CRAB Light chain ratio 99: you have smoldering myeloma, let’s give you len for two years Light chain ratio 101: you have myeloma, let’s give you quad, transplant and indefinite treatment for life! 🤦🏽‍♂️😡

Hello #MedTwitter from Rhode Island, the smallest state in US. My name is Syed Maaz Tariq and I am an ECFMG certified IMG, I have applied for #Match2024 in #InternalMedicine. I am currently working at a primary care center as a medical scribe 💻 AAMC ID: 16044654 I am

I’m really proud of this study. After 20 years since inception, we got the final completion from CIRB today. The trial changed myeloma treatment— a lot of lives saved simply by reducing steroid dose. ECOG-ACRIN Cancer Research Group Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Mike Thompson, MD, PhD, FASCO Yelak Biru The Lancet Oncology thelancet.com/journals/lanon…

A comprehensive review of the impact of obesity on plasma cell disorders [Oct 15, 2021] Richa Parikh Syed Maaz Tariq, MD Marinac & Urvi Shah Leukemia Journal ow.ly/8Wfv50GsImL #mmsm #cametab cc UAMS Myeloma Center UAMS Cancer Hem-Onc Fellows Network

SCI-HUB 😎 #SciHub

As a result, we spend billions on common drugs that other countries spend a fraction of the price on. Some drugs we pay 10 or 100 times more!!

Super excited to present my work at National Comprehensive Cancer Network (NCCN) annual conference. Hoping to network with like minded colleagues and mentors for more projects ahead. #NCCN2025 #cancer #Lymsm #mmsm #oncology

🚨Not all myeloma targets are equal ! Though BCMA CAR-T therapies are game changing but resistance can develop. Non-BCMA therapies are vital for patients with relapses. Humbled to be featured by Oncology Learning Network as a PGY-1 IM resident for our work on non-BCMA CAR-T cell Therapy